What are the brand names of Dapagliflozin (SGLT2 inhibitor)?

From the Guidelines

Dapagliflozin is marketed under several brand names worldwide, with Farxiga being the most common brand name in the United States and Forxiga being used in many other countries including Europe, Canada, and Australia.

Brand Names and Availability

• Dapagliflozin is also available in combination with metformin under the brand names Xigduo XR (US) and Xigduo (elsewhere) 1.
• Another combination product containing dapagliflozin and saxagliptin is marketed as Qtern.

Indications and Uses

• These medications are SGLT2 inhibitors primarily used to treat type 2 diabetes by helping the kidneys remove excess sugar from the bloodstream through urine.
• More recently, dapagliflozin has also been approved for heart failure treatment and chronic kidney disease, even in patients without diabetes, due to its beneficial effects on cardiac and renal function beyond glucose control 2.

Clinical Trials and Evidence

• The DAPA-HF trial specifically evaluated the effects of dapagliflozin on the primary outcome of a composite of worsening heart failure or cardiovascular death in individuals with New York Heart Association (NYHA) class II, III, or IV heart failure and an ejection fraction of 40% or less 2.
• Dapagliflozin treatment had a lower risk of the primary outcome (HR 0.74 [95% CI 0.65–0.85]), lower risk of first worsening heart failure event (HR 0.70 [95% CI 0.59–0.83]), and lower risk of cardiovascular death (HR 0.82 [95% CI 0.69–0.98]) compared with placebo 2.

From the Research

Dapagliflozin Brand Names

• Dapagliflozin is known by the brand names Forxiga® and Farxiga® 3, 4

Overview of Dapagliflozin

• Dapagliflozin is an orally administered sodium-glucose co-transporter-2 (SGLT2) inhibitor used in the management of patients with type 2 diabetes 3
• It reduces renal glucose reabsorption by inhibiting the transporter protein SGLT2 in the renal proximal tubule, thereby increasing urinary glucose excretion and reducing blood glucose levels 3

Efficacy and Tolerability

• Numerous well-designed clinical trials with dapagliflozin have consistently demonstrated reductions in glycosylated haemoglobin, fasting plasma glucose levels, and bodyweight 3, 4
• Dapagliflozin is generally well tolerated, with a low risk of hypoglycaemia, although the incidence varies depending on background therapy 3, 4
• Genital mycotic infections (particularly in women) are the most common adverse events associated with dapagliflozin treatment 3, 5, 6, 7